The New York Times reports an inexpensive steroid drug has shown a clear, significant benefit in reducing coronavirus-related deaths following a 6,000 patient trial study in Britain.
The steroid, dexamethasone, reduced deaths by a third in patients receiving ventilation, and by a fifth in patients receiving only oxygen treatment, the scientists said. They found no benefit from the drug in patients who did not need respiratory support.
“Dexamethasone is the first drug to be shown to improve survival in Covid-19,” said Peter Horby, professor of emerging infectious diseases at the University of Oxford, and one of the chief investigators for the trial, said in a statement. “The survival benefit is clear and large in those patients who are sick enough to require oxygen treatment.”
Professor Horby said that dexamethasone should now become the “standard of care in these patients,” noting that it is inexpensive, widely available and can be used immediately.
More from Sky News in the UK below.